Clinical Trial: A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07409428) titled 'A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL' on Jan. 28.

Brief Summary: This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Study Start Date: March 10

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Intervention: DRUG: HMPL-760

Patients will receive HMPL-760 once daily (QD) orally.

DRUG: HMPL-760 Placebo

Patients will...